Quest for the right Drug

|
עמוד הבית / קרדילוק 2.5 / מידע מעלון לרופא

קרדילוק 2.5 CARDILOC 2.5 (BISOPROLOL HEMIFUMARATE)

תרופה במרשם תרופה בסל נרקוטיקה ציטוטוקסיקה

צורת מתן:

פומי : PER OS

צורת מינון:

טבליה : TABLETS

Posology : מינונים

4.2 Posology and method of administration

Hypertension, Angina pectoris:
Treatment should principally be initiated gradually with low doses, which are then increased slowly. In all cases the dosage should be adjusted individually, in particular according to the pulse rate and therapeutic success.

Hypertension
The recommended dosage is 5 mg bisoprolol fumarate once daily.
In milder forms of hypertension (diastolic blood pressure up to 105 mmHg) therapy with 2.5 mg once daily may be adequate.
If necessary, the dosage may be increased to 10 mg once daily. Any further increase of dosage is justified only in exceptional cases.
The maximum recommended dosage is 20 mg once daily.

Coronary heart disease (angina pectoris)
The recommended dosage is 5 mg bisoprolol fumarate once daily.
If necessary, the dosage may be increased to 10 mg once daily. Any further increase of dosage is justified only in exceptional cases.
The maximum recommended dosage is 20 mg once daily.

CHF

Standard treatment of CHF consists of an ACE inhibitor (or an angiotensin receptor blocker in case of intolerance to ACE inhibitors), a beta-blocker, diuretics, and when appropriate cardiac glycosides. Patients should be stable (without acute failure) when bisoprolol treatment is initiated.
It is recommended that the treating physician should be experienced in the management of chronic heart failure.
Transient worsening of heart failure, hypotension, or bradycardia may occur during the titration period and thereafter.
Posology:
Titration phase
The treatment of stable chronic heart failure with bisoprolol requires a titration phase The treatment with bisoprolol is to be started with a gradual uptitration according to the following steps:
- 1.25 mg once daily for 1 week, if well tolerated increase to - 2.5 mg once daily for a further week, if well tolerated increase to - 3.75 mg once daily for a further week, if well tolerated increase to - 5 mg once daily for the 4 following weeks, if well tolerated increase to - 7.5 mg once daily for the 4 following weeks, if well tolerated increase to - 10 mg once daily for the maintenance therapy.
The maximum recommended dose is 10 mg once daily.
Close monitoring of vital signs (heart rate, blood pressure) and symptoms of worsening heart failure is recommended during the titration phase. Symptoms may already occur within the first day after initiating the therapy.
Treatment modification
If the maximum recommended dose is not well tolerated, gradual dose reduction may be considered.

In case of transient worsening of heart failure, hypotension, or bradycardia reconsideration of the dosage of the concomitant medication is recommended. It may also be necessary to temporarily lower the dose of bisoprolol or to consider discontinuation.
The reintroduction and/or uptitration of bisoprolol should always be considered when the patient becomes stable again.
If discontinuation is considered, gradual dose decrease is recommended, since abrupt withdrawal may lead to acute deterioration of the patients condition.
Treatment of stable chronic heart failure with bisoprolol is generally a long-term treatment.
Renal or hepatic impairment
There is no information regarding pharmacokinetics of bisoprolol in patients with chronic heart failure and with impaired hepatic or renal function. Uptitration of the dose in these populations should therefore be made with additional caution.
Elderly
No dosage adjustment is required.
Paediatric population
There is no paediatric experience with bisoprolol, therefore its use cannot be recommended in paediatric patients.
Method of administration:
Bisoprolol tablets should be taken in the morning and can be taken with food. They should be swallowed with liquid and should not be chewed.

שימוש לפי פנקס קופ''ח כללית 1994 לא צוין
תאריך הכללה מקורי בסל לא צוין
הגבלות לא צוין

בעל רישום

UNIPHARM LTD, ISRAEL

רישום

128 07 30654 00

מחיר

0 ₪

מידע נוסף

עלון מידע לרופא

12.12.12 - עלון לרופא

עלון מידע לצרכן

08.03.22 - עלון לצרכן אנגלית 08.03.22 - עלון לצרכן ערבית 11.12.12 - עלון לצרכן 16.08.20 - החמרה לעלון 23.08.21 - החמרה לעלון

לתרופה במאגר משרד הבריאות

קרדילוק 2.5

קישורים נוספים

RxList WebMD Drugs.com